Thursday, February 24, 2011
Theratechnologies Inc., of Montreal, announced a new clinical program for muscle wasting in chronic obstructive pulmonary disease (COPD) using the company's lead compound, tesamorelin, a human growth hormone releasing factor analogue. The company said it will develop tesamorelin in muscle wasting in patients with COPD as its second indication.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.